Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15708301 | 1.00 | TRPM2 (0.37) | TRPM2MAPK1TSHRPOLBCYP2C9 | |
| SCHEMBL25615668 | 1.00 | TRPM2 (0.37) | TRPM2MAPK1TSHRPOLBCYP2C9 | |
| SCHEMBL21407673 | 0.85 | TRPM2 (0.35) | TRPM2MAPK1TSHRPOLBCYP2C9 | |
| SCHEMBL14487698 | 0.85 | TRPM2 (0.35) | TRPM2MAPK1TSHRPOLBCYP2C9 | |
| SCHEMBL25615667 | 0.85 | TRPM2 (0.35) | TRPM2MAPK1TSHRPOLBCYP2C9 | |
| SCHEMBL21420075 | 0.85 | LMNA (0.34) | TSHRGAAKDM4E | |
| SCHEMBL20078963 | 0.83 | LMNA (0.44) | TSHRGAAHTTALDH1A1 | |
| SCHEMBL19890879 | 0.83 | LMNA (0.44) | TSHRGAAHTTALDH1A1 | |
| SCHEMBL14487345 | 0.83 | LMNA (0.44) | TSHRGAAHTTALDH1A1 | |
| SCHEMBL19875685 | 0.83 | LMNA (0.44) | TSHRGAAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4585/4885MAPK1 3513/4885TSHR 3015/4885 |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4585/4885MAPK1 3513/4885TSHR 3015/4885 |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4495/4885MAPK1 3385/4885TSHR 3048/4885 |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | TRPM2 3360/4885MAPK1 4303/4885TSHR 4869/4885 |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4585/4885MAPK1 3513/4885TSHR 3015/4885 |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4585/4885MAPK1 3513/4885TSHR 3015/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4585/4885MAPK1 3513/4885TSHR 3015/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | TRPM2 3360/4885MAPK1 4303/4885TSHR 4869/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | TRPM2 3423/4885MAPK1 4199/4885TSHR 4874/4885 |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | TRPM2 4585/4885MAPK1 3513/4885TSHR 3015/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | TRPM2 3612/4885MAPK1 2221/4885TSHR 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.